While the business of Biotage continues to perform well, following consultation with the Board Tomas Blomquist will leave his role as CEO & President of Biotage AB with immediate effect. The Chairman of the Board, Torben Jørgensen, has been appointed by the Board of Directors as interim CEO while the process of recruiting a new CEO is finalized.
- “The Board wishes to thank Tomas Blomquist for the four years he has led the company. During turbulent times, not the least the effects from geopolitical events and a global pandemic, the company has doubled in size under his leadership. As we embark on a new growth phase in Biotage we have agreed that there is a need for change and that new leadership with a different profile is needed to take an already successful company to the next level “ says Torben Jørgensen, Chairman of the Board.
As Torben Jørgensen takes on the role as interim CEO, he has resigned as Chairman of the Board but he will remain as a Board member. Kieran Murphy has been appointed as Chairman of the Board during Torben Jørgensen’s period as interim CEO, which has been decided in dialogue with the Nomination Committee. Kieran Murphy also takes Torben Jørgensen’s role as acting member of the Nomination Committee.
Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in drug discovery and development and diagnostics, analytical testing and water and environmental testing.
Biotage is contributing to sustainable science with the goal to make the world a healthier, greener and cleaner place – HumanKind Unlimited.
Our customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research and contract manufacturers as well as clinical, forensic and academic laboratories in addition to organizations focused on food safety, clean water and environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs appr. 700 people worldwide. The Group had sales of 1,566 MSEK in 2022 and our products are sold in more than 80 countries. Biotage’s share (BIOT) is listed in the Large Cap segment on the NASDAQ Stockholm.